Literature DB >> 11382695

A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis.

U Barnas1, A Schmidt, G Seidl, A Kaider, P Pietschmann, G Mayer.   

Abstract

Chronic renal failure leads to a reduction of bone mineral density (BMD). Therefore, noninvasive methods to evaluate BMD are also used regularly in this patient population. In this study, we compared the results of two widely used methods, quantitative computed tomography (QCT) of the lumbar spine and dual x-ray absorptiometry (DXA) at different sites in 90 patients on chronic hemodialysis. Additionally, we also determined various clinical and biochemical data to assess their relationship to BMD at the different measurement sites. A total of 75% of our patients was found to have reduced BMD, and 25% had an average z-score below -2. Z-scores obtained by the different methods and at the different measurement sites within an individual patient varied considerably from completely normal to severely reduced values. Multivariate analyses using clinical and biochemical parameters showed lower values of BMD at all measurement sites after transplantation and marginally higher values after parathyroidectomy, which was seen only in DXA measurement at the femoral neck. We conclude from our study that determination of BMD in chronic hemodialysis patients yields highly variable results, depending on the technique used. As long as the exact clinical relevance of these results has not been determined, regular routine measurement of isolated sites of BMD cannot be advocated in this patient population.

Entities:  

Mesh:

Year:  2001        PMID: 11382695     DOI: 10.1053/ajkd.2001.24529

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.

Authors:  Fettah Fevzi Ersoy; Stauros Ploumis Passadakis; Paul Tam; Evaggelos Dimitros Memmos; Pericles Konstantinos Katopodis; Cetin Ozener; Fehmi Akçiçek; Taner Camsari; Kenan Ateş; Rezzan Ataman; John George Vlachojannis; Athanasios Nicholas Dombros; Cengiz Utaş; Tekin Akpolat; Semra Bozfakioğlu; George Wu; Ibrahim Karayaylali; Turgay Arinsoy; Panagiotis Charalampos Stathakis; Mahmut Yavuz; John Dimitrios Tsakiris; Chrysostomos Athanasios Dimitriades; Mehmet Emin Yilmaz; Meral Gültekin; Binnur Karayalçin; Mehmet Yardimsever; Dimitrios George Oreopoulos
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients.

Authors:  Jan Mares; Kristina Ohlidalova; Sylvie Opatrna; Jiri Ferda
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

3.  Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.

Authors:  Konstantinos K Doumouchtsis; Alkis I Kostakis; Stergios K Doumouchtsis; Marios P Tziamalis; Charalambos P Stathakis; Evanthia Diamanti-Kandarakis; Dimitrios Dimitroulis; Despoina N Perrea
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

Review 4.  Osteoporosis in the elderly with chronic kidney disease.

Authors:  F Fevzi Ersoy
Journal:  Int Urol Nephrol       Date:  2006-11-11       Impact factor: 2.266

5.  Factors associated with low bone mass in the hemodialysis patients--a cross-sectional correlation study.

Authors:  Guey-Shiun Huang; Tzong-Shinn Chu; Meei-Fang Lou; Shiow-Li Hwang; Rong-Sen Yang
Journal:  BMC Musculoskelet Disord       Date:  2009-06-04       Impact factor: 2.362

Review 6.  Vitamin D and UV exposure in chronic kidney disease.

Authors:  Rolfdieter Krause
Journal:  Dermatoendocrinol       Date:  2013-01-01

7.  Diagnosis of low bone mass in CKD-5D patients.

Authors:  Gustav A Blomquist; Daniel L Davenport; Hanna W Mawad; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Clin Nephrol       Date:  2016-02       Impact factor: 0.975

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.